Emergent (Bioport), DoD Amend Contract
http://www.chron.com/disp/story.mpl/ap/fn/4925370.html
ROCKVILLE, Md. — Biopharmaceutical company Emergent BioSolutions Inc. on Wednesday said it will accelerate delivery of its BioThrax anthrax vaccine to the Department of Defense.
The company said it expects $20 million in revenue in the second quarter due to the amended agreement with the Defense Department to accelerates delivery of its Biothrax vaccine.
Emergent will deliver 900,000 doses of the vaccine during the quarter ending June 30 or shortly after that.
Emergent said it is also preparing a response to a proposal request from the Department of Defense for a follow-on contract to supply up to 14 million doses of BioThrax to the military. The one-year contract has three option years.
Shares rose 41 cents, or 4.4 percent, to $9.80 during afternoon trading. The stock has traded between $8.33 and $17.75 during the past 52 weeks.
ROCKVILLE, Md. — Biopharmaceutical company Emergent BioSolutions Inc. on Wednesday said it will accelerate delivery of its BioThrax anthrax vaccine to the Department of Defense.
The company said it expects $20 million in revenue in the second quarter due to the amended agreement with the Defense Department to accelerates delivery of its Biothrax vaccine.
Emergent will deliver 900,000 doses of the vaccine during the quarter ending June 30 or shortly after that.
Emergent said it is also preparing a response to a proposal request from the Department of Defense for a follow-on contract to supply up to 14 million doses of BioThrax to the military. The one-year contract has three option years.
Shares rose 41 cents, or 4.4 percent, to $9.80 during afternoon trading. The stock has traded between $8.33 and $17.75 during the past 52 weeks.
